Australia's most trusted
source of pharma news
Posted 11 February 2026 PM
The abrupt change in CSL leadership and the release of disappointing earnings initially wiped around $15 billion from the value of Australia's largest pharma, before a small recovery.
The late announcement yesterday that Paul McKenzie had been replaced by Gordon Naylor caused panic on the sharemarket, with the ASX delaying the end of trading of shares in CSL due to a relatively new rule. The Austrailan Financial Review noted the sell-off last night wiped five per cent off the value of CSL, and stripped more than 14 points from the S&P/ASX20.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.